# Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

> **NCT03881488** · PHASE1 · COMPLETED · sponsor: **Compass Therapeutics** · enrollment: 100 (actual)

## Conditions studied

- Locally Advanced Solid Tumor
- Metastatic Cancer
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Mesothelioma
- Melanoma
- Head and Neck Cancer

## Interventions

- **DRUG:** CTX-471
- **DRUG:** Pembrolizumab (KEYTRUDA®)

## Key facts

- **NCT ID:** NCT03881488
- **Lead sponsor:** Compass Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-17
- **Primary completion:** 2025-05-21
- **Final completion:** 2025-05-21
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881488, "Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03881488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*